Medicus Pharma CEO to Present at 2026 Summits
CEO Raza Bokhari will highlight investigational oncology products at upcoming conferences in New York and Abu Dhabi.
Updated on Oct. 27, 2026 in Biotech
Live Poll
Do you generally trust the clinical potential of products announced by small biotechnology companies?
Medicus Pharma CEO Raza Bokhari is scheduled to present at the BioFuture 2026 conference in New York City on October 27, 2026. He will also deliver a keynote at the Global Biotechnology Summit in Abu Dhabi beginning November 11, 2026.
Why it matters
These appearances provide a platform for Medicus Pharma to detail the progress of its investigational oncology pipeline, including antibody-drug conjugates and targeted skin cancer therapies. The presentations aim to provide insight into the company's clinical research priorities.
The company is advancing the CD228V antibody-drug conjugate using the vedotin linker-payload platform and the Teverelix GnRH antagonist. Additionally, the SkinJect product utilizes a dissolvable microneedle patch to deliver doxorubicin for Gorlin syndrome.
The players
Raza Bokhari
He is the Chief Executive Officer of Medicus Pharma and will serve as the featured speaker at both upcoming biotechnology industry events.
Medicus Pharma
This publicly traded biotechnology company specializes in the development of investigational oncology products and antibody-drug conjugates.
The details
Medicus Pharma is focusing its research on the SKNJCT-005 study for Gorlin syndrome and proof-of-concept trials for CD228V in melanoma. The presentations will outline these clinical investigations and the company's broader approach to targeted cancer treatments.
Timeline
October 27, 2026: BioFuture panel presentation occurs between 2:00 and 2:55 p.m. in New York City.
October 28, 2026: The BioFuture conference concludes.
November 11, 2026: The Global Biotechnology Summit begins.
November 12, 2026: CEO Raza Bokhari delivers the summit keynote at 11:45 a.m. in Abu Dhabi.
The Tech Race
The firm is positioning its specialized oncology products to compete against existing treatments for basal cell carcinoma and melanoma. The announcement regarding upcoming summit presentations follows the formal regulatory progress marked by the FDA authorized SKNJCT-005 study.
The presentations offer investors and industry observers insights into the company's progress on clinical studies that may eventually impact treatment standards. No immediate change to patient care or product availability is expected as these assets remain in the investigational phase.
The takeaway
Medicus Pharma is prioritizing its clinical development pipeline to address niche oncology conditions like Gorlin syndrome. Stakeholders should monitor these summit presentations for updates on trial progress and long-term research strategy.
Further reading
For more information on recent advancements in the field, visit the Biotech section.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you generally trust the clinical potential of products announced by small biotechnology companies?
